| From : | IVANUSA, Marijan <ivanusam@who.int> |
| To : | Zaza Sopromadze |
| Subject : | Изменения в Примерном перечне ВОЗ основных лекарственных средств / Summaries of changes to the WHO Model List of Essential Medicines ... |
| Cc : | Sopo Belkania; mdarakhvelidze@moh.gov.ge; HABICHT; Triin <habichtt@who.int>; THOMSON; Sarah <thomsons@who.int>; KLIMIASHVILI; Rusudan <klimiashvilir@who.int>; KURTSIKASHVILI; Giorgi <kurtsikashvilig@who.int> |
| Received On : | 20.03.2018 11:36 |
Dear Mr. Zaza Sopromadze, deputy minister,
Below please find links to the updated WHO lists of essential medicines.
The updates were the result of the 21st meeting of the WHO Expert Committee on the Selection and Use of Essential Medicines, which took place in Geneva, Switzerland, on 27–31 March 2017. The goal of the meeting was to review and update the 19th EML and the 5th EMLc. The Expert Committee considered 92 applications, including proposals to add 41 new medicines and extend the indications for 6 existing listed medicines, and 5 applications to delete medicines from the lists.
The meeting also included a comprehensive review of the antibacterials listed in sections 6.2.1 and 6.2.2 and their use in the treatment of 21 common, priority infectious syndromes; 5 paediatric infectious diseases; and 3 sexually transmitted infections. In accordance with approved procedures, the Expert Committee evaluated the scientific evidence for the comparative effectiveness, safety and cost–effectiveness of the medicines.
The objective of the 3 documents is to communicate these changes to national counterparts involved in the evidence-based selection of: medicines for inclusion in national essential medicines lists (NEMLs), medicines for inclusion in reimbursement programmes, and medicine formularies for use in primary, secondary and tertiary care.
These documents are available in both English and Russian and address the following areas:
· changes to the 2017 EML and EMLc;
· consideration of antibacterial medicines (section 6.2) as part of the revisions to the 2017 EML and EMLc;
· consideration of diabetes medicines (section 18.5) as part of the revisions to the 2017 EML and EMLc.
These summary documents do not replace the report of the WHO Expert Committee 2017, and should be read in conjunction with the full report.
http://www.who.int/medicines/publications/essentialmedicines/en/
The lists are available in English and Russian.
Hopefully this information is useful as SSA has included some of the medicines to the basic UHC package.
Best regards,
Marijan Ivanusa
WHO Representative
Head of WHO Country Office Georgia
Office location: 81 Vasil Barnov Street, 0179 Tbilisi, Georgia
Mailing address: UN House, 9 Rapiel Eristavi Street, 0179 Tbilisi, Georgia
Mobile 1: +995 599 305 207
Mobile 2/EU/private: +386 40 528 639
Email: ivanusam@who.int
Skype: who-ivanusam
GPN: 74211
Web: www.euro.who.int